Genelux (GNLX)Director sold ~$29K

~$29K

Approx. value · 10K sh @ $2.90

483K

Holds after · shares reported

Traded

Mar 2, 2026

Filed

Mar 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 30, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 30, 2025, Paul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation (the “ Company ”), effective immediately. Appointment of Jason Litten, M.D. as Chief Medical Officer On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Company’s Chief Medical Officer, effective as of January 2, 2026 (the “ Effective Date ”).”
2. Mar 2, 2026 · this disclosureInsiderDirector sold ~$29K of GNLX shares in the open market

What came next

1. Mar 19, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
2. Mar 24, 2026Insider · 4 peopleInsiders: 4 sales (~$14K)
3. Mar 25, 2026InsiderOfficer sold ~$602 of GNLX shares in the open market
4. May 11, 2026Insider · 4 peopleInsiders: 4 sales (~$13K)
5. Jun 1, 2026InsiderDirector sold ~$30K of GNLX shares in the open market
6. Jun 3, 2026InsiderOfficer sold ~$563 of GNLX shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Genelux

For Genelux, OQRO holds 6 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GNLX page.

Other recent filings by John Thomas, Director

• SEC Form 4 at Genelux (GNLX)Jun 3, 2026
• SEC Form 4 at Genelux (GNLX)Dec 3, 2025

The full history of John Thomas, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Genelux

• SEC Form 4Sep 2, 2026
• SEC Form 4Sep 2, 2026
• SEC Form 4Sep 2, 2026
• SEC Form 4Aug 5, 2026
• SEC Form 4Aug 5, 2026
• SEC Form 4Aug 5, 2026

Everything OQRO holds on this company is on its GNLX page.